COVID-19 disease has become a very serious global health problem. Treatments for severe forms are urgently needed to lower mortality. Any procedure that improves these forms should be considered, especially those devoid of serious side effects.There is not enough published information on the use of allogeneic convalescent plasma (ACP) in the treatment of severe forms of COVID-19. The use of ACP can be combined with other treatments and has very few adverse effects. It takes 10-14 days for SARS-CoV2-infected patients to produce virus-neutralizing antibodies: within that time they can develop serious complications and die. Injecting PAC into patients with severe forms of COVID-19 shortens the period of risk while the patient produces the antibodies.

Inclusion Criteria:

• Patients with SARS-CoV2 infection who have had a serious evolution and are in an ICU
• With or without ventilatory assistance
• Treated or not with hydroxychloroquine 200 mg. every 12 hours
• Indistinct sex
• Older than 18 years
• Signed informed consent

Exclusion Criteria:

• Patients treated with the following medications: azithromycin, ritonavir / lopinavir, remdesivir, interferons, ruxolinitib, tocilizumab.
• Patients with severe kidney failure who require replacement therapy.